Mildronate (Meldonium Dihydrate)

Meldonium Dihydrate blocks the enzyme γ‑butyrobetaine hydroxylase, decreasing the synthesis of carnitine. Lower carnitine levels limit fatty‑acid transport into mitochondria, prompting heart cells to rely more on glucose oxidation, which requires less oxygen and therefore supports cardiac function during ischemia.

The dosage of Mildronate is determined by the prescribing physician based on the patient’s clinical condition, severity of disease, and response to therapy. The prescriber will select the appropriate amount, infusion rate, and treatment duration.

Safety data for Meldonium in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Mildronate differs from traditional anti‑ischemic drugs such as nitrates or beta‑blockers by targeting myocardial metabolism rather than vascular tone. It shifts energy production toward glucose, which can be more efficient under low‑oxygen conditions, offering a complementary mechanism to standard therapies.

Mildronate for injection should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial to maintain stability.

Mildronate is given intravenously by a qualified healthcare professional. The solution is infused over a prescribed period, typically under clinical monitoring to observe any immediate reactions and ensure proper dosing.

Serious adverse events, although rare, can include significant hypotension, arrhythmias, severe allergic reactions (anaphylaxis), marked liver enzyme elevation, renal impairment, and thrombocytopenia. Patients should be monitored closely for these signs, especially during the initial treatment phase.

Mildronate is contraindicated in patients with known hypersensitivity to Meldonium or any excipients in the formulation. Caution is advised for individuals with severe uncontrolled hypertension, active bleeding disorders, or those receiving incompatible medications without appropriate monitoring.